Study by TGen and collaborators documents different outcomes for males and females at various ages

PHOENIX, Ariz. — Sept. 22, 2021 — Findings from a national study by researchers at Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and external collaborators suggest that sex and age are crucial factors in the care and survival of patients with malignant brain tumors and other central nervous system (CNS) cancers.

Continue reading→

RMRM 2021 Scorpion Pit Competition
Tucson Marriott University Park, Tucson, Arizona
Thursday, October 21, 2021 5:00 – 7:00 PMContinue reading→

Trial provides proof of concept for this new metabolically targeted, rapidly acting technology platform for brain tumors and other lethal cancersContinue reading→

New 3D Microelectrode Arrays will Advance Organoid-Based Models for Neurological and Neurodegenerative DiseasesContinue reading→

The pace of medical innovation is accelerating around the world and right here in the Arizona bioscience sector. Biomedical innovators are pioneering in the fields of diagnostics, treatments, medical devices, and health technologies.Continue reading→

TGen-led study suggests that modifications of DNA at specific genomic sites correlate with levels of fibrosis in NAFLD and could be used to diagnose the severity of this conditionContinue reading→

TUCSON, Ariz., September 16, 2021 — Critical Path Institute (C-Path) today announced the appointment of Jonathan M. Davis, M.D., as Senior Advisor in Pediatrics working with its International Neonatal Consortium (INC) and advising on drug and device development in infants and children, effective immediately.Continue reading→

C-Path, NORD and FDA host annual meeting, demonstration and launch of new rare disease data and analytics platform.Continue reading→

• Roche launches the Digital Pathology Open Environment, encouraging collaboration among software developers to improve patient outcomes and expand personalised healthcare through innovative image analysis tools
• Artificial intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment
• Open digital pathology environments can break down barriers to allow for rapid technology advances across industry and research partners, which is critical in developing next-generation diagnostic tests

Continue reading→

“Science-based companies are in a unique position to leverage what they know to find solutions to new challenges,” stated AZBio president & CEO Joan Koerber-Walker.  “PathogenDx is an innovative company that has productized multiple assays to combat the war with pathogens.  The ability to adapt is at the core of the company’s DNA, making them a shining example of how Arizona Bioscience Companies are stepping up to meet the challenges of our time.”Continue reading→